



FACULTY OF NURSING, PHARMACY AND HEALTH PROFESSIONS

Pathophysiology for Pharm D

Course # PHARM 35

1st Sem. 2018/2019

Date 10/12/2018

Instructor: Dr. Wail Hammoudeh, FACP

1) Name the differences Between Extracellular (ECF) and Intracellular (ICF),

- The body fluids volume is 60% of body weight.
- ICF = 40%.
- ECF = 20%:
 - 80% of ECF is interstitial Fluid (the fluid between cells in tissues)-
 - 20% of ECF is blood plasma.
- ECF = large amounts of *sodium, chloride, calcium and bicarbonate ions*.
- ICF = large amounts of *potassium, magnesium, and phosphate ions*

2) Describe the free radicals & their mechanism of action of in cellular injury

- Free radicals (ROS) are generated as by-products of normal cell metabolism
- Free radicals have one or more unpaired electrons in their outer shell.
- Exogenous sources include *tobacco smoke, organic solvents, pollutants, radiation, bacterial infections and pesticides*.
- Examples of free radicals include Superoxide (O₂⁻) , hydroxyl radicals (OH⁻) , hydrogen peroxide(H₂O₂) and Hydroperoxyl radicals
- Free radicals are inactivated by antioxidant enzymes within the body such as catalase, glutathione peroxidase (Gpx) and superoxide dismutase (SOD).
- Free radicals can injure cells through:
 - Peroxidation of membrane lipids (free radicals "steal" electrons from the lipids in cell membranes, resulting in cell damage)
 - Damage of cellular proteins
 - Mutation of cellular DNA

3) Describe the cell cycle.

- The *cell cycle is a repeating series of events* that cells go through.
- It includes growth, DNA synthesis, and cell division.
- There are two growth phases (G1 & G2), and cell division includes *mitosis*.
- The cell cycle is *controlled by regulatory proteins* at three key checkpoints (G1, G2 & M) in the cycle.
- These checkpoints signal the cell to either start or delay the next phase of the cycle.
- Cancer is a disease that occurs when the cell cycle is no longer regulated. Cancer cells grow rapidly and may form a mass of abnormal cells called a *tumor*.

4) Describe the Growth regulatory genes & "Drivers" of Cancer.

- The genetic changes that contribute to cancer tend to affect *three main types of genes* that involved in regulation of cell proliferation & growth; *proto-oncogenes, tumor suppressor genes* and *DNA repair genes*.
- These *changes "mutations"* are sometimes called "**drivers**" of cancer.
 - **Proto-oncogenes** are involved in *normal cell growth and division*. When mutated they may become cancer-causing genes (or oncogenes), allowing cells to grow and survive when they should not.
 - **Tumor suppressor genes** *restrain (تقيّد) cell growth and division*; loss of function results in unregulated growth and may divide in an uncontrolled manner.
 - **DNA repair genes** are involved in *fixing damaged DNA*. DNA repair genes – when *mutated, become faulty* and tend to develop additional mutations in other genes.
- Together, *these altered, or "mutated," Genes* may cause the cells to become *cancerous*.

5) Describe the role of the adenomatous polyps in colorectal cancers.

- There are 2 types of polyps:
 - Sessile: Base is attached to the wall
 - Pedunculated: Mucosal stalk from polyp to wall
- Between 70 and 90 % of colorectal cancers arise from *adenomatous polyps* (Adenomas), and 10 to 30 % arise from *sessile adenomas*.
- The *larger the polyp, the greater the potential for malignancy*.
- Diminutive polyps (5 mm or less in diameter) have a *negligible malignant potential*.
- Polyps with a diameter of 5 to 10 mm are considered small, whereas polyps greater than 10 mm in diameter are considered large.
- **Polyps larger than 2 cm in diameter have a 50 percent chance of becoming malignant over time.**
- If polyps are not removed, they continue to grow and can become cancerous.

6) Describe the Blood coagulation

- Blood coagulation is the process in which *fibrin* protein strands wrap around (يلتف حول) the platelet plug to form an insoluble clot.
- The process of blood coagulation occurs through two separate, but related pathways called :
 - The *intrinsic coagulation pathway* and
 - The *extrinsic coagulation pathway*
- Intrinsic coagulation pathway:
 - Initiated by protein factors **found circulating in the blood**.

- Activation of initial clotting factor *XII* (Hageman factor) *occurs after Vessel Injury* through contact with *exposed collagen or damaged endothelium*
- Extrinsic coagulation pathway:
 - Initiated by protein factors *located in the tissues*.
 - Activation of extrinsic pathway occurs when factor *III* (thromboplastin) is *released from tissues* to activate clotting factor *VII*.

7) Name the risk factors for Breast cancer in women

TABLE 1. RISK FACTORS FOR BREAST CANCER IN WOMEN
<ul style="list-style-type: none"> • Advanced age • First-degree relative with breast cancer • Genetic predisposition: BRCA1 or BRCA2 gene • Early menarche • Late menopause • Nulliparity • First full-term pregnancy after age 30 • Personal history of breast, ovarian, or endometrial cancer • Obesity/increased BMI • High breast-tissue density • Long-term or high-dose estrogen replacement therapy • Prior radiation to breast area, as in treatment for Hodgkin's disease
<p>BMI = body mass index. Source: National Institutes of Health.</p>

Obesity is associated with a *twofold increase* in the risk of breast cancer in *postmenopausal women* whereas among *premenopausal women* it is associated with a *reduced incidence*.

8) Describe the Natural inhibitors (Anticoagulants)

- Antithrombin III – inhibits factor X and thrombin
- Heparin from basophils and mast cells potentiates effects of antithrombin III (together they inhibit IX, X, XI, XII and thrombin)
- Antithromboplastin (inhibits „tissue factors” – tissue thromboplastins)
- Protein C and S – activated by thrombin; degrade factor Va and VIIIa

9) Describe the process of Erythropoiesis.

- Erythropoiesis is the part of hematopoiesis that deals with the *production of RBCs*.
- A major regulator of *red blood cell* production is the hormone *erythropoietin* (Epo) *which is a glycoprotein*.
- The major site of Epo production is the kidney, while the liver is the main *extrarenal site of Epo* production.
- Epo secretion is stimulated by hypoxia (O₂ deficiency), which is detected by an *oxygen sensor located in the kidney*.
- The erythropoietin that is produced acts directly on stem cells in the bone marrow to promote the proliferation, maturation and release of *immature red cells* (Reticulocytes)

10) Define and describe the manifestations of Polycythemia

- Polycythemia = number of RBC in circulation is greatly increased.
- Manifestations
 - Increased blood volume and viscosity
 - Increased risk of thrombus
 - Occlusion of small blood vessels
 - Hepatosplenomegaly from pooling of blood
 - Impaired blood flow to tissues (ischemia)
 - Headache , Dizziness, Weakness ,Increased blood pressure, Itching / sweating

11) Describe the pathophysiology of leukemia

- The pathophysiology of leukemia isn't completely understood, but like other types of cancer; it is due to the **mutation in the DNA** of the *Hematopoietic stem cells (HSCs)* of the bone marrow.
- Once a mutation in DNA occurs that can't be repaired, the *abnormal or immature form white blood cells* can freely *replicate and become essentially "immortal"*.
- These abnormal white blood cells **no longer function normally**.
- **Over time**, these leukemic cells *multiply* and *crowd out* (تزاحم) the normal cells of the bone marrow that do function properly. *This increases the risk of infections* – one of the most common causes of death in people with leukemia.
- This overabundance of abnormal white blood cells also *reduces the number of red blood cells and platelets*, leading to anemia and bleeding problems.
- The **abnormal and immature (blast) Leukemic cells** *spill out* into the blood and invade other tissues such as the *spleen, liver, lymph nodes and bone* and cause tissue destruction.

12) Describe shortly the 4 types of leukemia.

- ALL most common type of childhood leukemia (80%)
- AML is the **most common adult leukemia**. Auer rods seen *in the leukemic blasts* of AML.
- CLL is caused by an *abnormal proliferation* of lymphocytes. Hypogammaglobulinemia *occurs in > 50% of patients*. Low IgM (*patients are predisposed to infections*).
- CML is a proliferation of *primitive hematopoietic stem cells*(*hypercellular*). **Philadelphia chromosome** (Chromosome 22 containing the fused BCR-ABL gene) *leads to the production of an abnormal protein with tyrosine kinase activity causing proliferation of the myeloid mass, which leads to CML*.

13) Describe the types of Immunity

Innate or Natural or Nonspecific Immunity		Adaptive or Acquired or Specific
NONSPECIFIC DEFENSE MECHANISMS		SPECIFIC DEFENSE MECHANISMS (IMMUNE SYSTEM)
First line of defense	Second line of defense	Third line of defense
<ul style="list-style-type: none"> • Skin • Mucous membranes • Secretions of skin and mucous membranes 	<ul style="list-style-type: none"> • Phagocytic white blood cells • Antimicrobial proteins • The inflammatory response 	<ul style="list-style-type: none"> • Lymphocytes • Antibodies

14) Describe the Cells of the Immune System

- ❖ **The myeloid progenitors** develop into the cells that *respond early and nonspecifically to infection*.
 - **Monocytes** turn into **Macrophages** *in body tissues* and gobble up foreign invaders.
 - **Neutrophils** engulf bacteria upon contact and send out warning signals.
 - Granule-containing cells such as **eosinophils** *attack parasites*, while basophils release granules containing histamine and other allergy-related molecules.
- ❖ **Lymphoid precursors** develop into lymphocytes.
 - **Lymphocytes** *respond later in infection*. They mount a more specifically tailored attack after *antigen-presenting cells* such as dendritic cells or macrophages, display their catch in the form of antigen fragments.

- The **B cell** turns into a **plasma cell** that produces and releases into the bloodstream *thousands of specific antibodies*. *Antibodies attach to a specific antigen* and make it easier for the immune cells *to destroy the antigen*.
- The **T cells** *attack antigens directly* and help control the immune response. They also release chemicals, known as cytokines, which control the entire immune response.

15) Describe Hodgkin's Lymphoma.

- Hodgkin lymphoma is a *malignant proliferation* of ***B-cell lymphocyte***, that begins in a single node or group of nodes and *then spread to contiguous (the next in sequence) lymph node*, (rarely skipping areas-*which is more common-* in NHL).
- Involvement of *retroperitoneal lymph nodes, spleen, liver, and bone marrow occurs after the lymphoma becomes generalized*.
- It is characterized by the presence of of ***Reed-Sternberg cells (RS) in lymph nodes & in Blood***.
- ***Curability >75% (NHL Curability < 25%)***

16) Describe the Multiple Myeloma

- Multiple myeloma is a ***plasma cell cancer*** in the ***bone marrow*** (which is found in the big bones of the body, such as the ***skull, pelvis, ribs, and sternum***, as well as the long bones of the legs (***femur***) and arms (***humerus***).
- Plasma cells are ***B lymphocyte cells*** that secrete ***immunoglobulins (Antibodies)***.
- It is called multiple myeloma because myeloma cells can occur in ***multiple bone marrow sites in the body***.
- Accounts for 10% to 15% of all hematologic malignancies.
- It is characterized by the uncontrolled proliferation of an abnormal clone of plasma cells, which secrete huge amounts of ***monoclonal proteins (also called M protein or paraprotein such as Bence Jones proteins)*** or immunoglobulins mainly IgG, IgA .
- Most patients are **> 40 years**; median age **65** years.

17) Define Atherosclerosis

- Atherosclerosis is a *syndrome affecting arterial blood vessels*, a *chronic inflammatory response* in the walls of arteries starts when ***high blood pressure, smoking, or high cholesterol damage the endothelium***.
- At that point, cholesterol plaque formation begins.
- ***Calcification of plaques*** may occur over time.
- ***Significant narrowing of the blood vessel lumen*** can occur over time.
- Atherosclerosis tends to happen throughout the body.
- Atherosclerosis usually causes *no symptoms until middle or older age*.

18) Describe the pathophysiology of deep vein thrombus (DVT) with examples.

- Three main factors that may contribute to the formation of a thrombus:
 - 1) Hypercoagulable State (Blood Clots: *Malignancy, trauma or surgery of lower extremities ,hip, abdomen or pelvis*)
 - 2) Circulatory Stasis (Decreased Blood Flow : *Atrial fibrillation, venous obstruction from tumor ,obesity or pregnancy*)
 - 3) Vascular Wall Injury (Endothelial Injury : *Heart valve disease or replacement , atherosclerosis*)

19) Describe the Protective actions of Nitric Oxide (NO) and the results of its deficiency

- Endothelial NO has the following actions
 - Smooth muscle relaxation and vasodilatation
 - Essential for regulation of blood pressure
 - Reduces proliferation of vascular smooth muscle
 - Protects blood vessel intima from injurious consequences of platelet aggregation
- **Nitrite oxide** causes the blood vessels to dilate in order to increase blood flow.
- Endothelial Dysfunction causes a reduction in the secretion of nitric oxide.
- Lack of nitrite oxide causes the blood vessels to constrict →Atherosclerosis →
↑Systemic vascular resistance → Hypertension

20) Describe the role of renal artery stenosis in the secondary hypertension .

- Renal artery disease can cause of narrowing of the vessel lumen (stenosis). This stenosis reduces the pressure at the *afferent arteriole in the kidney*. Reduced arteriolar pressure and reduced renal perfusion stimulate Renin release by the kidney (*Juxtaglomerular apparatus*)
- *Reduced arteriolar pressure* and reduced renal perfusion stimulate Renin release by the kidney.
- This increases circulating angiotensin II (AII) and aldosterone.
- Aldosterone hormones increase blood volume by enhancing renal reabsorption of sodium and water. (Increase Cardiac Output)
- Increased AII causes systemic vasoconstriction and enhances sympathetic activity.
- Chronic elevation of AII promotes cardiac and vascular hypertrophy.
- The net effect of these renal mechanisms is an increase in blood volume that augments cardiac output by the Frank-Starling mechanism.
- **Therefore, hypertension caused by renal artery stenosis results from both an increase in systemic vascular resistance and an increase in cardiac output.**